<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2008</study_start_year><condition>Colorectal Neoplasm</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Neoplasm</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2055331</full_dataset_link><location>South Korea</location><study_start_month>4</study_start_month><keyword>Oxaliplatin</keyword><keyword>Capecitabine</keyword><keyword>S-1</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer</name><description>The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (OS) and Oxaliplatin and Capecitabine (XELOX) in patients with advance or recurrent colorectal cancer.</description><dates><creation>2008-04-15</creation></dates><accession>2055331</accession><cross_references><ClinicalTrials___gov>NCT00677144</ClinicalTrials___gov></cross_references></HashMap>